

Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020

<https://marketpublishers.com/r/B7D7E1F2136EEN.html>

Date: November 2020

Pages: 40

Price: US\$ 1,500.00 (Single User License)

ID: B7D7E1F2136EEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Basal Cell Nevus Syndrome (BCNS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Basal Cell Nevus Syndrome (BCNS) Understanding

Basal Cell Nevus Syndrome (BCNS): Overview

Basal Cell Nevus Syndrome (BCNS) is a multisystemic autosomal dominant disorder with a high penetrance and variable expressiveness. BCNS is a rare inherited condition characterised by multiple and early onset basal cell carcinomas and other tumours including melanoma, medulloblastoma, meningioma, breast carcinoma, non-Hodgkin lymphoma, and ovarian fibroma. The other names for BCNS include basal cell carcinoma nevus syndrome (BCCNS), Gorlin-Goltz syndrome, Gorlin syndrome, and nevoid basal cell carcinoma syndrome. These basal cell naevi are actually tiny basal cell carcinomas. It is mostly caused by mutations in the PTCH1 gene, sometimes

mutations in the SUFU and PTCH2 genes can cause a similar set of characteristics (phenotype).

Symptoms

The symptoms of Basal Cell Nevus Syndrome (BCNS) include:

Multiple basal cell carcinomas

Recurrent keratocystic odontogenic tumors of the jaws

Skeletal malformations (some affected individuals may have distinctive facial features)

Odontogenic cysts in the jaw

Broad forehead

Pits on palms and soles

Rib anomalies

Calcified falx cerebri (noted on skull X-ray)

Diagnosis

A diagnosis of Basal Cell Nevus Syndrome (BCNS) is based upon physical examination, detection of a pathogenic genetic variant, identification of characteristic clinical findings and imaging studies. The physical examination include oral exploration, cephalic diameter, craniofacial morphology, skin exploration, and evaluation of the palms and soles. Complementary tests includes skull X-rays, orthopantogram, chest X-ray, and spinal X-ray. Ultrasound examinations are used to diagnose cardiac and ovarian fibromas. The diagnosis of BCNS can be confirmed by the detection of a mutation of the PTCH gene.

Treatment

Treating the underlying cause of Basal Cell Nevus Syndrome (BCNS) a multidisciplinary

approach. The first-line of treatment for limited BCCs (nodular or aggressive) is usually surgical excision by standard or micro excisional/Mohs techniques. A wide variety of other treatment options for individuals with BCCs includes topical chemotherapy, drug therapy, cryotherapy, electrodesiccation and curettage, and photodynamic therapy. Future treatment options for BCNS patients include PTCH1- or SMO-specific targeted drugs which prevent the expression of tumor mediating genes within the hedgehog pathway.

Basal Cell Nevus Syndrome (BCNS) Emerging Drugs Chapters

This segment of the Basal Cell Nevus Syndrome (BCNS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Basal Cell Nevus Syndrome (BCNS) Emerging Drugs

Patidegib - PellePharm

Patidegib is an investigational topical treatment designed to mitigate the tumor burden in patients. It is designed to block the Smo signal so that the cells stop dividing and thus inhibits the hedgehog pathway rapidly along with a potentially shrink of BCCs.

PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for Patidegib Topical Gel in BCNS from the FDA, as well as Orphan Drug Designation in BCNS from EMA's Committee for Orphan Medicinal Products in the EU.

Vismodegib: Roche

Vismodegib is an experimental, oral smoothened antagonist and thus inhibits hedgehog pathway. It is under Phase II development for Basal cell nevus syndrome.

Further product details are provided in the report

Basal Cell Nevus Syndrome (BCNS): Therapeutic Assessment

This segment of the report provides insights about the different Basal Cell Nevus

Syndrome (BCNS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Basal Cell Nevus Syndrome (BCNS)

There are approx. 5+ key companies which are developing the therapies for Basal Cell Nevus Syndrome (BCNS). The companies which have their Basal Cell Nevus Syndrome (BCNS) drug candidates in the most advanced stage, i.e. phase III include, PellePharm.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Basal Cell Nevus Syndrome (BCNS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Basal Cell Nevus Syndrome (BCNS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Basal Cell Nevus Syndrome (BCNS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal Cell Nevus Syndrome (BCNS) drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Nevus Syndrome (BCNS) R&D. The therapies under development are focused on novel approaches to treat/improve Basal Cell Nevus Syndrome (BCNS).

Basal Cell Nevus Syndrome (BCNS) Report Insights

Basal Cell Nevus Syndrome (BCNS) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Basal Cell Nevus Syndrome (BCNS) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Basal Cell Nevus Syndrome (BCNS) drugs?

How many Basal Cell Nevus Syndrome (BCNS) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal Cell Nevus Syndrome (BCNS)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal Cell Nevus Syndrome (BCNS) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Basal Cell Nevus Syndrome (BCNS) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Palvella Therapeutics

Sun Pharmaceutical Industries

Roche

PellePharm

Asana BioSciences

Mayne Pharma

Key Products

Sirolimus topical

Sonidegib

Vismodegib

Patidegib

Gusacitinib

SUBA-Itraconazole

Contents

Introduction

Executive Summary

Basal Cell Nevus Syndrome (BCNS): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Basal Cell Nevus Syndrome (BCNS) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Basal Cell Nevus Syndrome (BCNS) companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Basal Cell Nevus Syndrome (BCNS) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Patidegib - PellePharm

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Vismodegib - Roche

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Sirolimus topical: Palvella Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Basal Cell Nevus Syndrome (BCNS) Key Companies

Basal Cell Nevus Syndrome (BCNS) Key Products

Basal Cell Nevus Syndrome (BCNS)- Unmet Needs

Basal Cell Nevus Syndrome (BCNS)- Market Drivers and Barriers

Basal Cell Nevus Syndrome (BCNS)- Future Perspectives and Conclusion

Basal Cell Nevus Syndrome (BCNS) Analyst Views

Basal Cell Nevus Syndrome (BCNS) Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Basal Cell Nevus Syndrome (BCNS)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Basal Cell Nevus Syndrome (BCNS)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/B7D7E1F2136EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B7D7E1F2136EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970